Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E D Smith

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Birth Defects Original Article Series|January 1, 1988
Operative management of high and intermediate anomalies in malesP A de Vries, T Dorairajan, F M Guttman, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1996
Measuring quality of life in culturally diverse populationsR B Warnecke, C E Ferrans, T P Johnson, et al.
ACS Chemical Biology|February 27, 2019
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent BindingChristopher P Tinworth, Hannah Lithgow, Lars Dittus, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 27, 2021
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation ApplicationsPeter Stacey, Hannah Lithgow, Xiao Lewell, et al.
Science (New York, N.Y.)|February 24, 2001
Genetic polymorphism in CX3CR1 and risk of HIV diseaseD H McDermott, J S Colla, C A Kleeberger, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping StrategyCatherine M Alder, Martin Ambler, Amanda J Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domainChristopher J Hobbs, Rino A Bit, Andrew D Cansfield, et al.
Communications Biology|March 22, 2020
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2Alina Mares, Afjal H Miah, Ian E D Smith, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Birth Defects Original Article Series|January 1, 1988
Operative management of high and intermediate anomalies in malesP A de Vries, T Dorairajan, F M Guttman, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1996
Measuring quality of life in culturally diverse populationsR B Warnecke, C E Ferrans, T P Johnson, et al.
ACS Chemical Biology|February 27, 2019
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent BindingChristopher P Tinworth, Hannah Lithgow, Lars Dittus, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 27, 2021
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation ApplicationsPeter Stacey, Hannah Lithgow, Xiao Lewell, et al.
Science (New York, N.Y.)|February 24, 2001
Genetic polymorphism in CX3CR1 and risk of HIV diseaseD H McDermott, J S Colla, C A Kleeberger, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping StrategyCatherine M Alder, Martin Ambler, Amanda J Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2002
Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domainChristopher J Hobbs, Rino A Bit, Andrew D Cansfield, et al.
Communications Biology|March 22, 2020
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2Alina Mares, Afjal H Miah, Ian E D Smith, et al.
Pageof 10